News

LecTec has reached a settlement with Endo Pharmaceuticals on outstanding patent litigation related to LecTec’s US Patent Nos 5536263 and 5741510. Endo Pharmaceuticals has agreed to make a

Genmab has posted revenues of $86m for the nine month period ended September 30, 2009. In the same period of 2008, Genmab recognised revenues of $131m. An operating

Ryogen has been awarded a new patent titled ‘Isolated Genomic Polynucleotide Fragments from Chromosome 7’. US patent No 7588915 has been issued by the US Patent and Trademark

Geron has presented new data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord

Endo Pharmaceuticals has agreed to make a one-time, $23m payment for the exclusive license to these two patents for use in the field of prescription pain medicines and

Access Pharmaceuticals (Access) has provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis. Access plans to commercially launch MuGard

Millennium Laboratories has reported the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta) by liquid chromatography/tandem mass spectrometry (LC-MS/MS). In addition,

Amsterdam Molecular Therapeutics (AMT) has reported positive result of duchenne muscular dystrophy (DMD) in an animal model with its proprietary gene therapy. Reportedly, the proof of concept studies

Nutri-Force Nutrition has reported the completion of its new manufacturing facility in Miami Lakes, Florida. This new facility was designed from the ground up to provide Nutri-Force’s customers